Expert Analysis
A $1 Million ALS Award Moves Mitochon’s Mitochondrial Drug Toward Phase 2
The ALS Association award will support a 24-week study of MP-101. Its mechanism and chemical history make careful dosing, transparent results and…
Astromech Raises $20 Million to Predict How Biology Changes
The Colossal Biosciences spinout is valued at a reported $3.8 billion as it builds AI models around evolutionary history. The financing is…
What Happened to Resveratrol, the Longevity Molecule That Was Everywhere?
Resveratrol moved from celebrated calorie-restriction mimetic to an instructive case study in the gap between animal biology and human longevity evidence.
The Hallmarks of Aging, Explained Without the Hype
The framework has become longevity science’s shared vocabulary. It is a map of interacting processes, not a checklist of proven human drug…
Life Biosciences Raises $80 Million as Reprogramming Enters the Clinic
The financing extends the company’s runway through its first human safety study. The valuation case still depends on safety, delivery and durable…
Retro Biosciences’ $1.8 Billion Bet Moves From Ambition to Clinical Risk
A new financing values Retro at $1.8 billion before the round. Its first clinical program makes the scientific and execution risks easier…